These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9630494)

  • 1. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones.
    Rehavi M; Goldin M; Roz N; Weizman A
    Brain Res Mol Brain Res; 1998 Jun; 57(1):31-7. PubMed ID: 9630494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs.
    Zucker M; Weizman A; Harel D; Rehavi M
    Neuropsychobiology; 2001; 44(4):187-91. PubMed ID: 11702019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression.
    Schwartz K; Yadid G; Weizman A; Rehavi M
    Brain Res; 2003 Mar; 965(1-2):174-9. PubMed ID: 12591135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.
    Zucker M; Weizman A; Rehavi M
    Life Sci; 2001 Sep; 69(19):2311-7. PubMed ID: 11669473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
    Ekue A; Boulanger JF; Morissette M; Di Paolo T
    J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.
    Rehavi M; Roz N; Weizman A
    Eur Neuropsychopharmacol; 2002 Jun; 12(3):261-8. PubMed ID: 12007678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient expression of the vesicular monoamine transporter during development in the rat thalamus and cortex.
    Leroux-Nicollet I; Costentin J
    Neurosci Lett; 1998 Jun; 248(3):167-70. PubMed ID: 9654335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
    Vilpoux C; Leroux-Nicollet I; Naudon L; Raisman-Vozari R; Costentin J
    Neuropharmacology; 2000 Apr; 39(6):1075-82. PubMed ID: 10727718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.
    Leroux-Nicollet I; Costentin J
    J Neural Transm Gen Sect; 1994; 97(2):93-106. PubMed ID: 7873127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo imaging of the brain vesicular monoamine transporter.
    Vander Borght TM; Kilbourn MR; Koeppe RA; DaSilva JN; Carey JE; Kuhl DE; Frey KA
    J Nucl Med; 1995 Dec; 36(12):2252-60. PubMed ID: 8523116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L; Crooks PA; Dwoskin LP
    J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific.
    Kilbourn M; Lee L; Vander Borght T; Jewett D; Frey K
    Eur J Pharmacol; 1995 May; 278(3):249-52. PubMed ID: 7589162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2.
    Finn JP; Edwards RH
    J Biol Chem; 1997 Jun; 272(26):16301-7. PubMed ID: 9195934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum.
    Naudon L; Leroux-Nicollet I; Boulay D; Costentin J
    J Neural Transm (Vienna); 2001; 108(4):431-44. PubMed ID: 11475010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration.
    Lu W; Wolf ME
    Brain Res Mol Brain Res; 1997 Oct; 49(1-2):137-48. PubMed ID: 9387873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nerve growth factor on dihydrotetrabenazine binding to PC12 cells.
    Adamson CR; Emley TE; Herbig LJ; Near JA
    Neurochem Int; 1997; 30(4-5):411-5. PubMed ID: 9106255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain.
    Kilbourn MR; Kemmerer ES; Desmond TJ; Sherman PS; Frey KA
    Exp Neurol; 2004 Aug; 188(2):387-90. PubMed ID: 15246838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra.
    Naudon L; Leroux-Nicollet I; Costentin J
    Neurosci Lett; 1994 May; 173(1-2):1-4. PubMed ID: 7523993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.